Cost-Effectiveness and Value of Information Analyses of Caplacizumab for the Treatment of Thrombotic Thrombocytopenic Purpura in Brazil
Although caplacizumab results in incremental QALYs, based on the proposed cost, caplacizumab is not cost effective from the SUS perspective, and VOI results indicate that further research would not be worthwhile.
Authors
- Dirk Müller (ORCID: https://orcid.org/0000-0002-5576-0192)
- Carlos Antônio Caramori (ORCID: https://orcid.org/0000-0002-0390-1061)
- Vânia dos Santos Nunes Nogueira (ORCID: https://orcid.org/0000-0001-9316-4167)
- Rafael Dezen Gaiolla (ORCID: https://orcid.org/0000-0002-9480-4995)
- Julia Simões Corrêa Galendi (ORCID: https://orcid.org/0000-0002-4832-7294)
- Hannes Rasch
Institutions
- University Hospital Cologne (DE)
- Universidade Estadual Paulista (Unesp) (BR)
Publication Details
- Journal
- Applied Health Economics and Health Policy
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1007/s40258-025-00968-7
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Universitätsklinikum Köln